Research programme: tolerogenic vaccines - Idogen

Drug Profile

Research programme: tolerogenic vaccines - Idogen

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idogen; Lund University
  • Class Dendritic cell vaccines
  • Mechanism of Action Factor VIII inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A; Renal transplant rejection

Most Recent Events

  • 12 Dec 2017 Idogen has patent protection for tolerogenic immune therapy for autoimmune diseases and transplant rejection in USA
  • 12 Dec 2017 Idogen has patent protection for tolerogenic immune therapy for autoimmune diseases and transplant rejection in Europe before December 2017
  • 11 May 2017 Preclinical trials in Renal transplant rejection (Prevention) in Sweden (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top